Administration of the prostacyclin analogue epoprostenol significantly decreased C-reactive protein (CRP) and, to some extent, IL-6 levels in patients with severe traumatic brain injury TBI compared to placebo and indicate an interesting option for treatment of TBI and warrants future larger studies 1)